All In Biotech

Drug Trial Radar · NCT00848770

Manipulation of Arterial Pressure in Acute Ischemic Stroke

Manipulation of Arterial Pressure Early in Non Thrombolysed Acute Ischemic Stroke: Effects on Death and Neurological Disability

Last checked: Nov 19, 2026Latest source record: Dec 31, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

240

Planned (sponsor's estimate)

Start

Jan 2008

Primary completion

Dec 2010

Study completion Dec 2010

Sponsor

Lead sponsor
Hospital de Clinicas de Porto AlegreAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 20, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a controlled clinical trial among non thrombolysed acute ischemic stroke patients to determine the effects of three levels of arterial pressure on death and neurological disability. After the admission in the vascular unit of the Emergency Department the patients are randomized to maintain during the first 24h the Systolic Arterial Pressure in tree levels of pressure: 140 to 160 mmHg; 161 to 180 mmHg and 181 to 200 mmHg. The end point of the study is the Modified Rankin score and mortality in three month after the discharge.

Conditions

  • Stroke, Acute

Interventions

  • Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)Drug

    Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS). NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min. NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min.

  • Esmolol, NPS or NORDrug

    We use one of the three drug to manipulate the systolic arterial pressure

  • manipulation of SAPDrug

    Esmolol or NPS or NOR

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ranking score and mortalityTime frame: Three month

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hospital de Clínicas de Porto Alegre/ UFRGS

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.